Role of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospital

Simple item page
dc.contributor.authorKurri, Nen_US
dc.contributor.authorTyagi, Ben_US
dc.contributor.authorKaushik, Aen_US
dc.contributor.authorGupta, Nikhilen_US
dc.contributor.authorAgarwal, A Ken_US
dc.contributor.authorSingh, B Men_US
dc.date.accessioned2023-06-17T08:20:42Z
dc.date.available2023-06-17T08:20:42Z
dc.date.issued2022-10
dc.description.abstractBackground: Clinical studies have correlated severe deterioration of COVID-19 patients due to excessive and uncontrolled production of cytokines. There is a pressing need to explore therapies, which could prevent the cytokine storm rather than terminating it. Aims and objectives: The aim of the study is to evaluate the effect of itolizumab on clinical outcomes of patients with moderate-severe COVID-19 disease admitted to ICU. The primary aim of the current study is to find out any mortality benefit in 14 days. The secondary aim is to assess the morbidity outcomes in terms of reduction in inflammatory markers and also the duration of hospital stays to assess the prognostication. Materials and methods: It is a retrospective case-control study in which laboratory-confirmed COVID-19 patients admitted to ICU were taken. A total of 62 patients were recruited, 31 patients received itolizumab (cases/treatment group) and 31 patients didn’t receive itolizumab (designated as controls). Results: Among the total patients recruited, 68% of the study population was male and 32% were female. A total of 12 patients expired among cases and 13 expired among controls. Overall mortality in both groups was noted to be almost similar. The control group showed mortality at lower computed tomography (CT) scores compared to the cases. There is a significant reduction in inflammatory markers, like interleukins-6 (IL-6) and D-dimer in cases compared to the control group. Conclusion: In conclusion, treating patients with cytokine storms before they require intubation/mechanical ventilation is crucial to preventing deaths. Itolizumab has shown no clinical benefit in critically ill COVID-19 patients, however, timely initiation of itolizumab therapy may serve as a key therapeutic option in preventing the mortality and morbidity outcomes in moderate-severe COVID-19 patients.en_US
dc.identifier.affiliationsAssociate Professoren_US
dc.identifier.affiliationsAssistant Professoren_US
dc.identifier.affiliationsPost Graduate Residenten_US
dc.identifier.affiliationsSenior Residenten_US
dc.identifier.affiliationsProfessor Emeritusen_US
dc.identifier.affiliationsProfessor, SMS & R Sharda Hospital, Greater Noida, Uttar Pradesh, Indiaen_US
dc.identifier.citationKurri N, Tyagi B, Kaushik A, Gupta Nikhil, Agarwal A K, Singh B M. Role of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospital. Journal of the Association of Physicians of India. 2022 Oct; 70(10): 35-38en_US
dc.identifier.issn0004 – 5772
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216294
dc.languageenen_US
dc.publisherAssociation of Physicians of Indiaen_US
dc.relation.issuenumber10en_US
dc.relation.volume70en_US
dc.source.urihttps://doi.org/10.5005/japi-11001-0114en_US
dc.titleRole of Itolizumab in the Treatment of COVID-19 Patients, Admitted to ICU at a Tertiary Care Hospitalen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JAPI2022v70n10p35.pdf
Size:
216.15 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of the Association of Physicians of India